Luminex (NASDAQ:LMNX) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Thursday.
LMNX has been the subject of a number of other research reports. William Blair restated a “market perform” rating on shares of Luminex in a report on Tuesday, February 13th. ValuEngine upgraded Luminex from a “hold” rating to a “buy” rating in a report on Tuesday. Finally, BTIG Research began coverage on Luminex in a research note on Friday, January 5th. They set a “buy” rating and a $24.00 target price for the company. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $22.33.
NASDAQ LMNX opened at $22.20 on Thursday. The company has a market capitalization of $987.25, a price-to-earnings ratio of 24.40, a P/E/G ratio of 2.09 and a beta of 0.11. Luminex has a fifty-two week low of $18.22 and a fifty-two week high of $22.59.
Luminex (NASDAQ:LMNX) last released its quarterly earnings results on Monday, February 12th. The medical instruments supplier reported $0.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.09 by $0.11. The firm had revenue of $78.20 million during the quarter, compared to analysts’ expectations of $77.33 million. Luminex had a return on equity of 8.48% and a net margin of 9.48%. Luminex’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.11 EPS. equities analysts forecast that Luminex will post 0.66 earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in LMNX. Creative Planning purchased a new position in shares of Luminex during the 4th quarter valued at approximately $198,000. UBS Asset Management Americas Inc. purchased a new position in shares of Luminex during the 4th quarter valued at approximately $206,000. Teacher Retirement System of Texas purchased a new position in shares of Luminex during the 4th quarter valued at approximately $270,000. Waldron LP purchased a new position in shares of Luminex during the 4th quarter valued at approximately $330,000. Finally, MetLife Investment Advisors LLC purchased a new position in shares of Luminex during the 4th quarter valued at approximately $372,000. Institutional investors own 80.75% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Luminex (LMNX) Rating Increased to Strong-Buy at BidaskClub” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/21/luminex-lmnx-rating-increased-to-strong-buy-at-bidaskclub.html.
Luminex Company Profile
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.